Identificación y validación de biomarcadores relacionados con FOXK1 en la retinopatía diabética

Diabetic retinopathy (DR) is a leading cause of irreversible blindness globally. Analysis of dataset GSE221521 showed significant upregulation of FOXK1 in DR patient blood. Functional studies indicated that silencing FOXK1 promotes endothelial cell apoptosis, migration, and neovascularization under high glucose via the p-AKT/AKT pathway, suggesting FOXK1 plays a key role in DR. This study aims to identify FOXK1-related biomarkers in DR.

We integrated two DR-related datasets (GSE221521 and GSE189005). Candidate genes were identified through differential expression analysis and Weighted Gene Co-expression Network Analysis (WGCNA). Biomarkers were subsequently screened using the Least Absolute Shrinkage and Selection Operator (LASSO) regression and validated based on their expression profiles. Further analyses included immune infiltration assessment, construction of a regulatory network, Gene Set Enrichment Analysis (GSEA), protein-protein interaction analysis via GeneMANIA, and drug prediction. The expression of key biomarkers was experimentally confirmed using reverse transcription quantitative polymerase chain reaction (RT-qPCR) on clinical peripheral blood samples.

From seven initial candidate genes, SPDEF and SLC25A41 were validated as diagnostic biomarkers. A predictive nomogram constructed with these biomarkers showed significant prognostic value. Immune infiltration analysis revealed significantly higher levels of Macrophages M0, monocytes, and activated CD4 memory T cells in DR samples. The constructed TF-miRNA-mRNA network included 10 transcription factors and 2 microRNAs, with FOXC1 and hsa-mir-335-5p co-regulating both SPDEF and SLC25A41. GSEA identified 74 associated pathways, including oxidative phosphorylation. Drug prediction suggested 25 potential targeting compounds, with resveratrol, daunorubicin, and digitoxigenin emerging as promising candidates. Finally, RT-qPCR analysis confirmed the significant downregulation of both SPDEF and SLC25A41 in DR patients, consistent with the bioinformatics findings.

Our findings suggest that SPDEF and SLC25A41 serve as potential biomarkers for DR, which may aid in early detection and provide new insights into the pathogenesis of the disease.